This company has been marked as potentially delisted and may not be actively trading. NYSE:ISR Isoray (ISR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Isoray Stock (NYSE:ISR) 30 days 90 days 365 days Advanced Chart Get Isoray alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.28▼$0.4252-Week Range N/AVolume145,000 shsAverage Volume290,697 shsMarket Capitalization$54.57 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewIsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The firm focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.Read More… Receive ISR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Isoray and its competitors with MarketBeat's FREE daily newsletter. Email Address ISR Stock News HeadlinesFrench ISR Label Revamp ReportNovember 22, 2023 | morningstar.comWhy IsoRay (ISR) Is Plunging TodayApril 24, 2023 | thestreet.comHas Trump finally met his match?Trump is making bold moves before even stepping back into the White House — securing border deals, brokering peace talks, and targeting sanctuary city funding. But according to 33-year Wall Street veteran Dylan Jovine, even Trump may not be able to fix what’s coming. Jovine believes there are five cracks forming in the U.S. economy — big enough to spark a 50% market crash, a 40% real estate plunge, and a surge in unemployment. That’s why he’s moved seven figures of his own money into a “safe haven” asset favored by names like Buffett, Musk, and Ackman. He’s released an emergency briefing explaining why the next 90 days could be critical for investors. April 23, 2025 | Behind the Markets (Ad)Why IsoRay (ISR) Stock Is Surging TodayMarch 16, 2023 | thestreet.comIsoRay (ISR) Reports Q2 Loss, Misses Revenue EstimatesFebruary 16, 2023 | finance.yahoo.comPerspective Therapeutics (formerly known as Isoray, Inc.) Announces Financial Results for the Quarter ended December 31, 2022February 16, 2023 | finance.yahoo.comIsoray, Inc.: Isoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.February 8, 2023 | finanznachrichten.deIsoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.February 7, 2023 | finance.yahoo.comSee More Headlines ISR Stock Analysis - Frequently Asked Questions How were Isoray's earnings last quarter? Isoray, Inc. (NYSE:ISR) released its earnings results on Wednesday, November, 10th. The company reported ($0.02) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by $0.01. The firm had revenue of $2.56 million for the quarter, compared to analyst estimates of $2.58 million. Isoray had a negative net margin of 115.91% and a negative trailing twelve-month return on equity of 17.12%. What other stocks do shareholders of Isoray own? Based on aggregate information from My MarketBeat watchlists, some other companies that Isoray investors own include Brainstorm Cell Therapeutics (BCLI), OPKO Health (OPK), Tesla (TSLA), Meta Platforms (META), Tonix Pharmaceuticals (TNXP) and Nano Dimension (NNDM). Company Calendar Last Earnings11/10/2021Today4/23/2025Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNYSE:ISR CIK728387 Webisoray.com Phone(509) 375-1202Fax509-267-3670EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,270,000.00 Net Margins-115.91% Pretax Margin-91.45% Return on Equity-17.12% Return on Assets-16.15% Debt Debt-to-Equity RatioN/A Current Ratio14.38 Quick Ratio13.99 Sales & Book Value Annual Sales$10.80 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.43 per share Price / BookN/AMiscellaneous Outstanding Shares142,110,000Free Float138,674,000Market Cap$54.57 million OptionableNot Optionable Beta1.48 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NYSE:ISR) was last updated on 4/23/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Isoray, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Isoray With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.